

GP-30165

PATENT

**Novel Compounds****Field of the Invention**

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

**Background of the Invention**

10 The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

15 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

**Summary of the Invention**

20 The present invention relates to MAGI, in particular MAGI polypeptides and MAGI polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, neuropathies, spinal injury, neuronal degeneration, neuromuscular disorders, psychiatric disorders and developmental disorders, cancer, stroke and inflammatory disorders, hereinafter referred to as "diseases of the invention." In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g. inhibitors) using the materials provided by the invention, and treating conditions associated with MAGI imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate MAGI activity or levels.

**Description of the Invention**

30 In a first aspect, the present invention relates to MAGI polypeptides. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1 or SEQ ID NO:5;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 35 99% identity to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;
- (c) an isolated polypeptide comprising the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;
- (e) the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6; and

Attorney Docket No.: 10200-003-999  
Serial No.: 09/830,972  
Reference: A04

Best Available Copy

05357206.073299

GP- 30165

2

- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;
- (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the reticulon family of polypeptides. They are therefore of interest because members of this family have been shown to display prominent, but not exclusive, expression in cells of the nervous system. Expression of one isoform of these polypeptides, neuroendocrine specific protein C (NSP-C) (J. Hens et al. Cell Tissue Res. 292:229-237, 1998), has been shown to correlate with neuronal differentiation. Alternative splicing of the genes of this family of polypeptides is known to generate differentially expressed isoforms with overlapping and distinct functions in different tissues (Geisler et al. Mamm. Genome 9:164-173, 1998). Amino acid similarity between members of this family of polypeptides with fragments of a high-molecular weight protein purified from bovine spinal cord (Spillmann et al. J. Biol. Chem. 273:15487-15493, 1998) indicates a potential role in axonal growth inhibition role for these proteins. Similarly, expression of neuroendocrine specific protein A (NSP-A) in specific cancerous cells (Senden et al. Histochem. Cell Biol. 108:155-165, 1997) may indicate a potential use of these polypeptides in the diagnosis and or treatment of cancers.

The detection of polynucleotides comprising portions of MAGI in human fetal brain and human adult spinal cord cDNA and an abundant >5kb mRNA isoform in human adult brain together with different transcripts potentially arising by alternative splicing in heart, lung, liver, kidney and skeletal muscle suggests that MAGI isoforms may similarly serve overlapping and distinct functions in these tissues. By analogy with the semaphorin family of neurite-modulatory polypeptides it might be postulated that these different isoforms would function in each of these tissues to control local innervation by distinct neuronal populations. Aberrant expression of specific isoforms within, for example, skeletal muscle would be predicted to alter motor and sensory neuron innervation in diseases such as amyotrophic lateral sclerosis (ALS).

The presence of characteristic signature polypeptides and highly hydrophobic regions in the polypeptide of the present invention suggests that its expression in regions of the nervous system and in tissues forming boundaries for growth may modulate growth and pathfinding both during development and following pathological or injurious processes.

Expression of the polypeptide of the invention, fragments thereof or alternatively spliced variants of the polypeptide on the surface of cells either naturally, as a secreted protein or following release by cellular damage, may act on other cells either through specific receptors or pathologically through non-specific interactions to modulate cell attachment, spreading, migration or growth. This inhibition might be expected to be either reversible or permanent possibly resulting in cell death.

The biological properties of the MAGI are hereinafter referred to as "biological activity of MAGI" or "MAGI activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of MAGI.

GP- 30165

3

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:6, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:6. Preferred fragments are biologically active fragments that mediate the biological activity of MAGI, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to MAGI polynucleotides. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:5;
- (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:5;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1 or SEQ ID NO:5;
- (d) the isolated polynucleotide of SEQ ID NO:1 or SEQ ID NO:5;
- (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;
- (f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:6;

GP- 30165

4

(g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6;

(h) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:6;

5 (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:5;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:6; and

10 (k) polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1 or SEQ ID NO:5, or an isolated polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1 or SEQ ID NO:5.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

20 Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

25 (a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:6;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:6;

30 (c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1 or SEQ ID NO:5; or

(d) is the RNA transcript of the DNA sequence of SEQ ID NO:1 or SEQ ID NO:5; and RNA polynucleotides that are complementary thereto.

The polynucleotide sequence of SEQ ID NO:1 shows homology with human neuroendocrine-specific protein C (Roebroek et al., J. Biol. Chem. 268: 13439-13447, 1993). The polynucleotide sequence of SEQ ID NO:1 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2. The polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The

0350208-072299

GP- 30165

5

polypeptide of the SEQ ID NO:2 is related to other proteins of the reticulon family, having homology and/or structural similarity with human neuroendocrine-specific protein C (Roebroek et al., J. Biol. Chem. 268: 13439-13447, 1993). The polynucleotide of SEQ ID NO:5 and the polypeptide encoded thereby, SEQ ID NO:6, is a variant of the polynucleotide of SEQ ID NO:1 and its encoded polypeptide, SEQ ID NO:2.

5 Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one MAGI activity.

The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:2 and SEQ ID NO:6.

10 Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

- (a) comprises a nucleotide sequence which has at least 95% identity, preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- 15 (b) has a nucleotide sequence which has at least 95% identity, preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (c) comprises the polynucleotide of SEQ ID NO:3; or
- (d) has a nucleotide sequence encoding a polypeptide which has at least 95% identity, even more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4;
- 20 as well as the polynucleotide of SEQ ID NO:3.

The present invention further provides for a polypeptide which:

- (a) comprises an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- 25 (b) has an amino acid sequence which is at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (c) comprises the amino acid of SEQ ID NO:4; and
- (d) is the polypeptide of SEQ ID NO:4;
- as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

30 The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognised by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. *et al*, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy.

35 Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

GP- 30165

6

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human fetal brain and spinal cord, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:5, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1 or SEQ ID NO:5, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides.

Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or SEQ ID NO:5 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:5 or a fragment thereof, preferably of at least 15 nucleotides.

GP- 30165

7

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat. Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al. (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

GP- 30165

8

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 or SEQ ID NO:5 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled MAGI nucleotide sequences. Perfectly matched



GP- 30165

9

sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by

5 nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising MAGI polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general

10 applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays,

15 competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:5, or a fragment or an RNA transcript thereof;
- (b) a nucleotide sequence complementary to that of (a);
- 25 (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:6 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2 or SEQ ID NO:6.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial

30 component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the

35 present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library).

GP- 30165

10

The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GencBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genomc.wi.mit.edu/>. The gene of the present invention maps to human chromosome 2p21.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include *in situ* hybridisation techniques to clones arrayed on a grid, such as cDNA microarray hybridisation (Scherena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature. The polypeptides of the present invention are expressed in brain, heart, liver, skeletal muscle, pancreas and kidney, based on Northern blot data provided in figure 1.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies

GP- 30165

11

produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

5 Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

10 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly,

GP- 30165

12

in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a MAGI activity in the mixture, and comparing the MAGI activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well microtiter plates but also emerging methods such as the nanowell method described by Schullck *et al.*, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and MAGI polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are

GP- 30165

13

not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, <sup>125</sup>I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include

5 biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some

10 cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and MAGI gene. The art

15 of constructing transgenic animals is well established. For example, the MAGI gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in

20 transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the

25 limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- 30 (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;
- which polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:6.

35 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

GP- 30165

14

### Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides

GP- 30165

15

may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, 1-12, in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol*, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci*, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1 or SEQ ID NO:5.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide.

Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

GP- 30165

16

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

5 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the  
10 polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

15 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

20 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

25 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for  
30 sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between-pairs of residues, one from each of the sequences being compared (as for identity) but also,  
35 where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

03/17/05 15:02 FAX 202 626 1700



GP- 30165

17

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devcreux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147, 195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal

GP- 30165

18

positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

$n_a$  is the number of nucleotide or amino acid differences,

$x_a$  is the total number of nucleotides or amino acids in SEQ ID NO:1 or SEQ ID NO:5 or SEQ ID NO:2 or SEQ ID NO:6, respectively,

$I$  is the Identity Index,

$\cdot$  is the symbol for the multiplication operator, and

in which any non-integer product of  $x_a$  and  $I$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog".

"Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

GP- 30165

19

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 \*\*\* discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

#### Example - Tissue distribution of human MAGI

A radioactively labelled DNA probe corresponding to the C-terminal 2kb of the MAGI open reading frame was hybridised with a Clontech MTN-1 filter containing equivalent loadings of mRNA from each of the indicated tissues and then washed to high stringency to only detect MAGI transcripts. The results are shown in figure 1. At least three bands are visible (>5kb, 2.4kb and <2kb). The largest transcript is present in adult brain and to a lesser degree in heart and skeletal muscle. The middle transcript is present at essentially similar levels in all tissues while the shortest transcripts is more specifically expressed, most abundantly in skeletal muscle, brain and kidney with low levels detectable in the pancreas.

Figure 1 Depicts a Northern blot showing tissue distribution of human MAGI. Lane 1 contains human adult heart RNA, lane 2 contains human adult brain RNA, lane 3 contains human placental RNA, lane 4 contains human adult lung RNA, lane 5 contains human adult liver RNA, lane 6 contains human adult skeletal muscle RNA, lane 7 contains human adult kidney RNA and lane 8 contains human adult pancreas RNA.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.



GP- 30165

21

GATTCATCTCCAATTGAAATTATAGATGAGTTCCCTACATTGATCAGTTCTAAAACGAT  
TCATTTTCTAAATTAGCCAGGGAATATACTGACCTAGAAGTATCCACAAAAGTGAAATT  
GCTAATGCCCCGGATGGAGCTGGGTCAATGCTTGCACAGAATTGCCCCATGACCTTTCT  
TTGAAGAACATACAACCCAAAGTTGAAGAGAAAAACAGTTTCTCAGATGACTTTTCTAAA  
5 AATGGCTCTGCTACATCAAAGGTGCTCTTATTGCCTCCAGATGTTTCTGCTTTGGCCACT  
CAAGCAGAGATAGAGAGCATAGTTAAACCCAAAGTTCTTGTGAAAGAAGCTGAGAAAAAA  
CTTCCTTCCGATACAGAAAAAGAGGACAGATCACCATCTGCTATATTTTTCAGCAGAGCTG  
AGTAAACCTCAGTTGTTGACCTCCTGTACTGGAGAGACATTAAGAAGACTGGAGTGGTG  
TTTGCTGCCAGCCTATTCTGCTGCTTTTATTGACAGTATTTCAGCATTTGTAGCGTAACA  
10 GCCTACATTGCTTGGCCCTGCTCTCTGTGACCATCAGCTTTAGGATATACAAGGTGTG  
ATCCAAGCTATCCAGAAATCAGATGAAGGCCACCCATTTCAGGGCATATCTGGAATCTGAA  
GTTGCTATATCTGAGGAGTTGGTTTCAAGTACAGTAATTTCTGCTTGGTCTGTGAAC  
TGACCGATAAAGGAACTCAGGCGCCTCTTCTAGTTGATGATTAGTTGATTCTCTGAAG  
TTTGAGTGTGATGTGGGTATTACCTATGTTGGTGCCTTGTTTAATGGTCTGACACTA  
15 CTGATTTTGGCTCTCATTTCAGTCTTCACTGTTCTGTTATTTATGAACGGCATCAGGCG  
CAGATAGATCATTATCTAGGACTTGCAAATAAGAATGTTAAAGATGCTATGGCTAAAATC  
CAAGCAAAAATCCCTCGATTGAAGCGCAAAGCTGAATGA

## SEQ ID NO:2

MEDLDQSPLVSSSDSPRPQPAFKYQFVREPEDEEEEEEEDEDELELEVLERKPA  
AGLSAAPVPTAPAAAPLMDFGNDFVPPAPRGLPAAPPVAPERQPSWDPSFVSSTVPAP  
SPLSAAAVSPSKLPEDDEPPARPPPPASVSPQAEVWTPPAPAPAAPPSTPAAPKRRG  
SSGSVDETLFALPAASEPVIRSSAENMDLKEQPGNTISAGQEDFPSVLLETAASLPSLSP  
LSAASFKEHEYLGNLSTVLPTGTLQENVSEASKEVSEKAKTLLIDRLTEFSELEYSEM  
25 GSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNILHNQQELPTALTCLVKEDEVV  
SSEKAKDSPNEKRVAVEAPMREEYADFKPFRVWEVKDSKEDSDMLAAGGKIESNLESKV  
DKKCFADSLEQTNHEKDSSESSNDDTSFPSTPEGIKDRPGAYITCAPFNAATESIATNIF  
PLLGDPTSENKTDEKKEIEKKAQIVTEKNTSTKTSNPFVAAQDSEIDYVTTNLTQVTE  
EVVANMPEGLTPDLVQACESSLNEVTGTKIAYETQMDLVQTSSEVMQESLYPAAQLCPSP  
30 EESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPYE  
EAMSVSLKKVSGIKKEIKPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSE  
MAKVEQPVPDHSSELVEDSSPDSEPVDFSDSIPDVFPQKQDETVMVLKESLTETSPESMI  
EYENKEKLSALPPEGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMBELSTAVY  
SNDDLFISKEAQIRETETFSDDSPIEIIDEFPTLISSKTDSPSKLAREYTDLEVSHKSEI  
35 ANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISPSDDPSKNGSATSKVLLLPDVSALAT  
QAEIESIVKPKVLVKEAEKKLPDTEKEDRSPSAIPSAELSKTSVVLDLYWRDIKKTGVV  
FGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIAIQKSDGHPFRAYLESE  
VAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDLSLKFVLMWVFTYVGALFNGLTL  
LILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAQIPGLKRKAE

## SEQ ID NO:3

GAAAATATGGACTTGAAGGAGCAGCCAGGTAACACTATTTCCGGCTGGTCAAGAGGATTTCC  
CCATCTGTCTGCTTGAACCTGCTGCTTCTNTTCTTCTCTGCTCTCTCAGCCGCT  
TCTTTCAAAGAACATGAATACCTTGGTAATTTGTCAACAGTATTACCCACTGAAGGAACA  
45 CTTCAAGAAAATGTCAAGGAGCTTCTAAGAGGTCTCAGAGAAGGCAAAAACCTCTACTC  
ATAGATAGAGATTTAACAGAGTTTTCAGAATTAGAATACTCAGAAATGGGATCATCGTTC

GP- 30165

22

AGTGTCTCTCCAAAAGCAGAATCTGCCGTAATAGTAGCAAATCCTAGGGAAGAAATAATC  
GTGAAAAATAAGATGAAGAAGACAAGTTAGTTAGTAATAACATCCTTCATANTCAACAA  
GAGTTACCTACAGCTCTTACTAAATTGGTTAAAGAGCATGAAGTTCTGTCTTCAGAAAAA  
GCAAAACACAGTTTTAATGAAAAGAGAGTTGCAGTGGAAAGCTCCTATGAGGGAGGAATAT  
5 GCAGACTTCAAACCTTTGAGCGAGTATGGGAAGTGAAAGATAGTAAGGAAGATAGTGAT  
ATGTTGGCTGCTGGAGGTAAAATCGAGAGCAACTTGGAAAGTAAAGTGGAATAAAAAATGT  
TTTGACAGATAGCCTTGAGCAAATAATCACGAAAAGATAGTGAGAGTAGTAATGATGAT  
ACTTCTTTCCCGAGTACGCCAGAAGGTATAAAGGATCGTTCAGGAGCATATATCACATGT  
GCTCCCTTTAACCAGCAGCAACTGAGAGCATTGCAACAAACATTTTTCTTTGTTAGGA  
10 GATCCTACTTCAGAAAAATAAGACCGATG

## SEQ ID NO:4

ENMDLKEQPONTISAGQEDFPSVLLETAASXPSLSPLSAASFKEHEYLGNLSTVLPTEGT  
LQENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSFKAESAVIVANPREZII  
15 VKNKDEEEKLVSNILHXQQLPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEY  
ADFKPFERVVEVKDSKEDSDMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSSESSND  
TSFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTD

## SEQ ID NO:5

ATGGAAGACCTGGACCACTCTCTGCTCGTCTCGGACAGCCCCACCCGGCCGCAG  
CCCCGCGTTCAAGTACCAGTTCGTGAGGGAGCCCCACCACGAGGAGGAAGAAGAGGAGGAG  
GAAGAGGAGGACGAGGACGAAGACCTGGAGGAGCTGGAGGTGCTGGAGAGGAAGCCCGCC  
GCCGGGCTGTCCGCGCCCCAGTGCCCCACCGCCCCCTGCCGCGCGCGCCCCCTGATGGAC  
TTCCGAAATGACTTCGTGCGCGCGCGCCCCGGGGACCCCTGCCGCGCGCTCCCCCGTC  
25 GCCCCGGAGCGGACGCGCTCTTGGGACCCGAGCCCGGTGCTGTCGACCGTGCCCGGCCA  
TCCCCGCTGTCTGCTGCCGAGTCTCGCCCTCCAAGCTCCCTGAGGACGACGAGCCTCCG  
GCCCCGCGCTCCCCCTCTCCCCCGGCCAGCGTGAGCCCCCAGGCAGAGCCCGTGTGAGCC  
CGCCAGCCCCGGCTCCCGCGCGCCCCCTCCACCCCGCGCGCCCAAGCGCAGGGGC  
TCCTCGGGCTCAGTGGTTGTTGACCTCTGTACTGGAGAGACATTAAGAAGACTGGAGTG  
30 GTGTTTGGTGCCAGCCTATTCTGCTGCTTTTATTGACAGTATTAGCATTGTGAGCGTA  
ACAGCCTACATTGCTTGGCCCTGCTCTCTGTGACCATCAGCTTTAGGATATACAAGGGT  
GTGATCCAAGCTATCCAGAAATCAGATGAAGGCCACCCATTGAGGGCATATCTGGAATCT  
GAAGTTGCTATATCTGAGGAGTTGGTTCAGAAGTACAGTAATTCTGCTCTTGGTCAITGT  
AACTGCACGATAAAGGAAGTCAAGCGCCTCTTCTTAGTTGATGATTAGTTGATTCTCTG  
35 AAGTTTGAGTGTGATGTGGGTATTTACCTATGTTGGTGCCTTGTAAATGGTCTGACA  
CTACTGATTTTGGCTCTCATTTCAGTCTTCTGTTTATTTATGAACGGCATCAG  
GCACAGATAGATCATTATCTAGGACTTGCAAATAAGAATGTTAAAGATGCTATGGCTAAA  
ATCCAAGCAAAAATCCCTGCATTGAAGCGCAAAGCTGAATGA

## SEQ ID NO:6

MEDLDQSPIVSSSDSPRPQPAFKYQFVREPEDEEEEEEEEEDEDEDELEEVLERKPA  
AGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSBSTVPAP  
SPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEVWTPAPAPAAPPPSTPAAPKRRG  
SSGSVVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKG  
45 VIQAIQKSDGCHPFRAYLESEVAISELVQKYSNSALGHVNCTIKELRRLFLVDDLVDLSL  
KFAVLMMVFTYVGFALFNLTLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAK

03/17/03 15:05 FAX 202 626 1700

GP- 30165

23

IQAKIPGLKRKAS

09359208.072299

GP- 30165

24

**What is claimed is:**

1. An isolated polypeptide selected from the group consisting of:

- (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;  
5 (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;  
(c) an isolated polypeptide comprising the polypeptide sequence of SEQ ID NO:2;  
(d) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;  
(e) the polypeptide sequence of SEQ ID NO:2; and  
10 (f) fragments and variants of such polypeptides in (a) to (e)

2. An isolated polynucleotide selected from the group consisting of:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;  
15 (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;  
(c) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;  
(d) the isolated polynucleotide of SEQ ID NO:1;  
(e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;  
20 (f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;  
(g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;  
(h) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2;  
25 (i) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides  
(j) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (i);  
(k) a polynucleotide sequence complementary to said isolated polynucleotide; and  
30 (l) polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

3. An antibody immunospecific for the polypeptide of claim 1.

35 4. An antibody as claimed in claim 3 which is a polyclonal antibody.

5. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.



GP-30165

25

6. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.

5

7. A recombinant host cell produced by the process of claim 6.

8. A membrane of a recombinant host cell of claim 7 expressing said polypeptide.

10 9. A process for producing a polypeptide which comprises culturing a host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

Sub  
A3

10. An isolated polynucleotide selected from the group consisting of:

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995

- (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3;
- (c) the polynucleotide of SEQ ID NO:3; and
- (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4.

11. A polypeptide selected from the group consisting of:

- (a) a polypeptide which comprises an amino acid sequence which has at least 95% identity to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (b) a polypeptide in which the amino acid sequence has at least 95% identity to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (c) a polypeptide which comprises the amino acid of SEQ ID NO:4;
- (d) a polypeptide which is the polypeptide of SEQ ID NO:4; and
- (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

12. An isolated polynucleotide selected from the group consisting of:

Sub  
A4

GP-30165

26

(a) an isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:5 over the entire length of SEQ ID NO:5;

(b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:5;

(c) the polynucleotide of SEQ ID NO:5; and

- 5 (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:6, over the entire length of SEQ ID NO:6.

13. A polypeptide selected from the group consisting of:

- 10 (a) a polypeptide which comprises an amino acid sequence which has at least 95% identity to that of SEQ ID NO:6 over the entire length of SEQ ID NO:6;

(b) a polypeptide in which the amino acid sequence has at least 95% identity to the amino acid sequence of SEQ ID NO:6 over the entire length of SEQ ID NO:6;

(c) a polypeptide which comprises the amino acid of SEQ ID NO:6;

(d) a polypeptide which is the polypeptide of SEQ ID NO:6; and

15 (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:5.

0359208.072299

GP- 30165

27

**Abstract**

MAGI polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing MAGI polypeptides and polynucleotides in diagnostic assays.

0359208-072299

## SEQUENCE LISTING

<110> MICHALOVICH, DAVID  
PRINJHA, RABINDER KUMAR

<120> NOVEL COMPOUNDS

<130> GP 30165

<140> TO BE ASSIGNED  
<141> 1999-07-22

<150> U.K. 9916898.1  
<151> 1999-07-19

<150> U.K. 9816024.5  
<151> 1998-07-22

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1  
<211> 3579  
<212> DNA  
<213> HOMO SAPIENS

<400> 1

atggaagacc	tggaccagtc	tcctctggtc	tcgtcctcgg	acagcccacc	ccggccgcag	60
cccgcgttca	agtaccagtt	cgtgagggag	cccaggagacg	aggaggaaga	agaggaggag	120
gaagaggagg	acgaggacga	agacctggag	gagctggagg	tgctggagag	gaagcccgcc	180
gccgggctgt	ccgcggcccc	agtccccacc	gccccctgcc	ccggcgcgcc	cctgatggac	240
ttcggaaaatg	acttctgtgc	gccggcgccc	cggggacccc	tgccggccgc	tccccccgtc	300
gccccggagc	ggcagccgtc	ttgggaccgc	agccccgtgt	cgtcgaccgt	gccccgcgca	360
tccccgctgt	ctgctgccgc	agtctcgccc	tccaagctcc	ctgaggacga	cgagccctcc	420
gccccggctc	ccccctctcc	ccccggccagc	gtgagccccc	aggcagagcc	cgtgtggacc	480
ccgcagccc	cggtctccgc	cgcgcccccc	tccaccccgg	ccgcgcccac	gcgcaggggc	540
tcctcgggct	cagtggatga	gacctttttt	gctcttctct	ctgcacttga	gcctgtgata	600
cgctcctctg	cagaaaaatat	ggacttgaag	gagcagccag	gtaacactat	ttcggctggg	660
caagaggatt	tcccactctgt	cctgcttgaa	actgctgctt	ctcttcttcc	tctgtctcct	720
ctctcagccg	cttctttcaa	agaacatgaa	taccttggtg	atttgtcaac	agtattaccc	780
actgaaggaa	cacttcaaga	aaatgtcagt	gaagcttcta	aagaggtctc	agagaaggca	840
aaaaactctac	tcatagatag	agattttaaca	gagttttcag	aattagaata	ctcagaaatg	900
ggatcatcgt	tcagttgtct	tccaaaagca	gaatctgccc	taatagtagc	aaatcctagg	960
gaagaaataa	tcgtgaaaaa	taaagatgaa	gaagagaagt	tagttagtaa	taacatcctt	1020
cataatcaac	aagagttacc	tacagctctt	actaaattgg	ttaaagagga	tgaagttgtg	1080
tccttcagaaa	aagcaaaaaga	cagtttttaac	gaaaagagag	ttgcagtgga	agctcctatg	1140
agggagggaat	atgcagactt	caaaccattt	gagcgagtat	gggaagtga	agatagtaag	1200
gaagatagtg	atatgttggc	tgctggagggt	aaaatcgaga	gcaacttgga	aagtaaaagt	1260
gataaaaaat	gttttgcaga	tagccttgag	caaactaatc	acgaaaaaga	tagtgagagt	1320
agtaatgatg	atacttcttt	ccccagtagc	ccagaaggta	taaaggatcg	tccaggagca	1380
tatatcacat	gtgctccctt	taacccagca	gcaactgaga	gcattgcaac	aaacattttt	1440
cctttgttag	gagatcctac	ttcagaaaat	aagaccgatg	aaaaaaaaat	agaagaaaaa	1500
aaggcccaaaa	tagtaacaga	gaagaatact	agcaccaaaa	catcaaaccc	ttttcttgta	1560
gcagcacagg	attctgagac	agattatgtc	acaacagata	atttaacaaa	ggtgactgag	1620

03/17/05 15:07 FAX 202 626 1700

gaagtcgtgg caaacatgcc tgaaggcctg actccagatt tagtacagga agcatgtgaa 1680  
 agtgaattga atgaagttac tgggtacaaag attgcttatg aaacaaaaat ggacttggtt 1740  
 caaacatcag aagttatgca agagtcactc talcctgcag cacagctttg cccatcattt 1800  
 gaagagtcag aagctactcc ttcaccagtt ttgcctgaca ttgttatgga agcaccattg 1860  
 aattctgcag ttcctagtgc tgggtgcttc gtgatacagc ccagctcctc accattagaa 1920  
 gcttcttcag ttaattatga aagcataaaa catgagcctg aaaaccccc accatatgaa 1980  
 gagggccatga gtgtatcact aaaaaaagta tcagggaataa aggaagaaat taaagagcct 2040  
 gaaaatatta atgcagctct tcaagaaaca gaagctcctt atatatctat tgcagtgtat 2100  
 ttaattaaag aaacaaagct ttctgctgaa ccagctccgg atttctctga ttattcagaa 2160  
 atggcaaaaag ttgaacagcc agtgctgat cattctgagc tagttgaaga ttcctcacct 2220  
 gattctgaac cagttgactt atttagtgat gattcaatac ctgacgttcc acaaaaaaaa 2280  
 gatgaaactg tgatgcttgt gaaagaaagt ctcaactgaga cttcatttga gtcaatgata 2340  
 gaatatgaaa ataaggaaaa actcagtgct ttgccacctg agggaggaaa gccatatattg 2400  
 gaatctttta agctcagttt agataacaca aaagataccc tgttacctga tgaagtttca 2460  
 acattgagca aaaaggagaa aattcctttg cagatggagg agctcagtag tgcagtttat 2520  
 tcaaatgatg acttatttat ttctaaggaa gcacagataa gagaaactga aacgttttca 2580  
 gattcatctc caattgaaat tatagatgag ttccctacat tgatcagttc taaaactgat 2640  
 tcattttcta aattagccag ggaatatact gacctagaag tatcccacaa aagtgaattt 2700  
 gctaattgcc cggatggagc tgggtcattg ccttgccacg aattgcccc tgacctttct 2760  
 ttgaagaaca tacaacccaa agttgaagag aaaatcagtt tctcagatga cttttctaaa 2820  
 aatgggtctg ctacatcaaa ggtgctctta ttgcctccag atgtttctgc tttggccact 2880  
 caagcagaga tagagagcat agttaaacoc aaagtctctg tgaagaagc tgagaaaaaa 2940  
 cttccttccg atacagaaaa agaggacaga tcaccatctg ctatatttt agcagagctg 3000  
 agtaaaaactt cagttgttga cctcctgtac tggagagaca ttaagaagac tggagtgggtg 3060  
 tttgggtgcc gctattctt gctgctttca ttgacagat tcagcattgt gacgtaaca 3120  
 gctacattg ccttggccct gctctctgtg accatcagct ttaggatata caaggggtgtg 3180  
 attccaagcta tccagaaatc agatgaaggc caccatttca gggcatatct ggaatctgaa 3240  
 gttgctatat ctgaggagtt ggttcagaag tacagtaatt ctgctcttgg tcatgtgaac 3300  
 tgcacgataa aggaactcag gcgcctcttc ttagttagtg atttagttga ttctctgaag 3360  
 tttgcagtgt tgatgtgggt atttacctat gttggtgcct tgtttaatgg tctgacacta 3420  
 ctgattttgg ctctcttctg aotcttcagt gttcctgtta tttatgaacg gcacaggcg 3480  
 cagatagatc attatctagg acttgcaaat aagaatgtta aagatgctat ggctaaaac 3540  
 caagcaaaaa tccctggatt gaagcgcaaa gctgaatga 3579

<210> 2  
 <211> 1192  
 <212> PRT  
 <213> HOMO SAPIENS

<400> 2

Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro  
 1 5 10 15  
 Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu  
 20 25 30  
 Asp Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp  
 35 40 45  
 Leu Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly Leu Ser  
 50 55 60  
 Ala Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala Pro Leu Met Asp  
 65 70 75 80  
 Phe Gly Asn Asp Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala  
 85 90 95  
 Ala Pro Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro  
 100 105 110  
 Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Val  
 115 120 125

03/17/05 15:07 FAX 202 626 1700

Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro  
 130 135 140  
 Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp Thr  
 145 150 155 160  
 Pro Pro Ala Pro Ala Ala Pro Pro Ser Thr Pro Ala Ala Pro  
 165 170 175  
 Lys Arg Arg Gly Ser Ser Gly Ser Val Asp Glu Thr Leu Phe Ala Leu  
 180 185 190  
 Pro Ala Ala Ser Glu Pro Val Ile Arg Ser Ser Ala Glu Asn Met Asp  
 195 200 205  
 Leu Lys Glu Gln Pro Gly Asn Thr Ile Ser Ala Gly Gln Glu Asp Phe  
 210 215 220  
 Pro Ser Val Leu Leu Glu Thr Ala Ala Ser Leu Pro Ser Leu Ser Pro  
 225 230 235 240  
 Leu Ser Ala Ala Ser Phe Lys Glu His Glu Tyr Leu Gly Asn Leu Ser  
 245 250 255  
 Thr Val Leu Pro Thr Glu Gly Thr Leu Gln Glu Asn Val Ser Glu Ala  
 260 265 270  
 Ser Lys Glu Val Ser Glu Lys Ala Lys Thr Leu Leu Ile Asp Arg Asp  
 275 280 285  
 Leu Thr Glu Phe Ser Glu Leu Glu Tyr Ser Glu Met Gly Ser Ser Phe  
 290 295 300  
 Ser Val Ser Pro Lys Ala Glu Ser Ala Val Ile Val Ala Asn Pro Arg  
 305 310 315 320  
 Glu Glu Ile Ile Val Lys Asn Lys Asp Glu Glu Glu Lys Leu Val Ser  
 325 330 335  
 Asn Asn Ile Leu His Asn Gln Gln Glu Leu Pro Thr Ala Leu Thr Lys  
 340 345 350  
 Leu Val Lys Glu Asp Glu Val Val Ser Ser Glu Lys Ala Lys Asp Ser  
 355 360 365  
 Phe Asn Glu Lys Arg Val Ala Val Glu Ala Pro Met Arg Glu Glu Tyr  
 370 375 380  
 Ala Asp Phe Lys Pro Phe Glu Arg Val Trp Glu Val Lys Asp Ser Lys  
 385 390 395 400  
 Glu Asp Ser Asp Met Leu Ala Ala Gly Gly Lys Ile Glu Ser Asn Leu  
 405 410 415  
 Glu Ser Lys Val Asp Lys Lys Cys Phe Ala Asp Ser Leu Glu Gln Thr  
 420 425 430  
 Asn His Glu Lys Asp Ser Glu Ser Ser Asn Asp Asp Thr Ser Phe Pro  
 435 440 445  
 Ser Thr Pro Glu Gly Ile Lys Asp Arg Pro Gly Ala Tyr Ile Thr Cys  
 450 455 460  
 Ala Pro Phe Asn Pro Ala Ala Thr Glu Ser Ile Ala Thr Asn Ile Phe  
 465 470 475 480  
 Pro Leu Leu Gly Asp Pro Thr Ser Glu Asn Lys Thr Asp Glu Lys Lys  
 485 490 495  
 Ile Glu Glu Lys Lys Ala Gln Ile Val Thr Glu Lys Asn Thr Ser Thr  
 500 505 510  
 Lys Thr Ser Asn Pro Phe Leu Val Ala Ala Gln Asp Ser Glu Thr Asp  
 515 520 525  
 Tyr Val Thr Thr Asp Asn Leu Thr Lys Val Thr Glu Glu Val Val Ala  
 530 535 540  
 Asn Met Pro Glu Gly Leu Thr Pro Asp Leu Val Gln Glu Ala Cys Glu  
 545 550 555 560  
 Ser Glu Leu Asn Glu Val Thr Gly Thr Lys Ile Ala Tyr Glu Thr Lys  
 565 570 575

00359208-072299

Met Asp Leu Val Gln Thr Ser Glu Val Met Gln Glu Ser Leu Tyr Pro  
 580 585 590  
 Ala Ala Gln Leu Cys Pro Ser Phe Glu Glu Ser Glu Ala Thr Pro Ser  
 595 600 605  
 Pro Val Leu Pro Asp Ile Val Met Glu Ala Pro Leu Asn Ser Ala Val  
 610 615 620  
 Pro Ser Ala Gly Ala Ser Val Ile Gln Pro Ser Ser Ser Pro Leu Glu  
 625 630 635 640  
 Ala Ser Ser Val Asn Tyr Glu Ser Ile Lys His Glu Pro Glu Asn Pro  
 645 650 655  
 Pro Pro Tyr Glu Glu Ala Met Ser Val Ser Leu Lys Lys Val Ser Gly  
 660 665 670  
 Ile Lys Glu Glu Ile Lys Glu Pro Glu Asn Ile Asn Ala Ala Leu Gln  
 675 680 685  
 Glu Thr Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile Lys Glu  
 690 695 700  
 Thr Lys Leu Ser Ala Glu Pro Ala Pro Asp Phe Ser Asp Tyr Ser Glu  
 705 710 715 720  
 Met Ala Lys Val Glu Gln Pro Val Pro Asp His Ser Glu Leu Val Glu  
 725 730 735  
 Asp Ser Ser Pro Asp Ser Glu Pro Val Asp Leu Phe Ser Asp Asp Ser  
 740 745 750  
 Ile Pro Asp Val Pro Gln Lys Gln Asp Glu Thr Val Met Leu Val Lys  
 755 760 765  
 Glu Ser Leu Thr Glu Thr Ser Phe Glu Ser Met Ile Glu Tyr Glu Asn  
 770 775 780  
 Lys Glu Lys Leu Ser Ala Leu Pro Pro Glu Gly Gly Lys Pro Tyr Leu  
 785 790 795 800  
 Glu Ser Phe Lys Leu Ser Leu Asp Asn Thr Lys Asp Thr Leu Leu Pro  
 805 810 815  
 Asp Glu Val Ser Thr Leu Ser Lys Lys Glu Lys Ile Pro Leu Gln Met  
 820 825 830  
 Glu Glu Leu Ser Thr Ala Val Tyr Ser Asn Asp Asp Leu Phe Ile Ser  
 835 840 845  
 Lys Glu Ala Gln Ile Arg Glu Thr Glu Thr Phe Ser Asp Ser Ser Pro  
 850 855 860  
 Ile Glu Ile Ile Asp Glu Phe Pro Thr Leu Ile Ser Ser Lys Thr Asp  
 865 870 875 880  
 Ser Phe Ser Lys Leu Ala Arg Glu Tyr Thr Asp Leu Glu Val Ser His  
 885 890 895  
 Lys Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala Gly Ser Leu Pro Cys  
 900 905 910  
 Thr Glu Leu Pro His Asp Leu Ser Leu Lys Asn Ile Gln Pro Lys Val  
 915 920 925  
 Glu Glu Lys Ile Ser Phe Ser Asp Asp Phe Ser Lys Asn Gly Ser Ala  
 930 935 940  
 Thr Ser Lys Val Leu Leu Leu Pro Pro Asp Val Ser Ala Leu Ala Thr  
 945 950 955 960  
 Gln Ala Glu Ile Glu Ser Ile Val Lys Pro Lys Val Leu Val Lys Glu  
 965 970 975  
 Ala Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys Glu Asp Arg Ser Pro  
 980 985 990  
 Ser Ala Ile Phe Ser Ala Glu Leu Ser Lys Thr Ser Val Val Asp Leu  
 995 1000 1005  
 Leu Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala Ser  
 1010 1015 1020

0035008-072259

Leu Phe Leu Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr  
 1025 1030 1035 104  
 Ala Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile  
 1045 1050 1055  
 Tyr Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro  
 1060 1065 1070  
 Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu Val  
 1075 1080 1085  
 Gln Lys Tyr Ser Asn Ser Ala Leu Gly His Val Asn Cys Thr Ile Lys  
 1090 1095 1100  
 Glu Leu Arg Arg Leu Phe Leu Val Asp Asp Leu Val Asp Ser Leu Lys  
 1105 1110 1115 112  
 Phe Ala Val Leu Met Trp Val Phe Thr Tyr Val Gly Ala Leu Phe Asn  
 1125 1130 1135  
 Gly Leu Thr Leu Leu Ile Leu Ala Leu Ile Ser Leu Phe Ser Val Pro  
 1140 1145 1150  
 Val Ile Tyr Glu Arg His Gln Ala Gln Ile Asp His Tyr Leu Gly Leu  
 1155 1160 1165  
 Ala Asn Lys Asn Val Lys Asp Ala Met Ala Lys Ile Gln Ala Lys Ile  
 1170 1175 1180  
 Pro Gly Leu Lys Arg Lys Ala Glu  
 1185 1190

<210> 3  
 <211> 868  
 <212> DNA  
 <213> HOMO SAPIENS  
 <220>  
 <221> unsure  
 <222> (91) (413)

<400> 3

gaaaatatgg	acttgaagga	gcagccaggt	aacactatatt	cggtcgggtca	agaggatttc	60
ccatctgtcc	tgcttgaac	tgctgcttct	nttccttctc	tgctcctctc	ctcagccgct	120
tctttcaaag	aacatgaata	ccttggtaat	ttgtcaacag	tattaccac	tgaagggaaca	180
cttcaagaaa	atgtcagtga	agcttctaaa	gaggtctcag	agaaggcaaa	aactctactc	240
atagatagag	atttaacaga	gttttcagaa	ttagaatact	cagaaatggg	atcatcggtc	300
agtgctcttc	caaaagcaga	atctgccgta	atagtagcaa	atcctaggga	agaaataatc	360
gtgaaaaata	aagatgaaga	agagaagtta	gttagtaata	acatccttca	tantcaacaa	420
gagttaccta	cagctcttac	taaattgggt	aaagaggatg	aagttgtgtc	ttcagaaaaa	480
gcaaaagaca	gttttaatat	aaagagagtt	gcagtggaag	ctcctatgag	ggaggaatat	540
gcagacttca	aaccatttga	gcgagtatgg	gaagtgaag	atagtaagga	agatagtgat	600
atgttggctg	ctggaggtta	aatcgagagc	aacttggaag	gtaaagtgga	taaaaaatgt	660
tttgcagata	gccttgagca	aactaatcac	gaaaaagata	gtgagagtag	taatgatgat	720
atctcttttc	ccagtcagcc	agaaggtata	aaggatcggt	caggagcata	tatcacatgt	780
gctcccttta	acccagcagc	aactgagagc	attgcaacaa	acatttttcc	tttgtttagga	840
gatcctactt	cagaaaaata	gaccgatg				868

<210> 4  
 <211> 289  
 <212> PRT  
 <213> HOMO SAPIENS  
 <220>  
 <221> unsure  
 <222> (31) (138)

<400> 4

00350208 072239



Glu Asn Met Asp Leu Lys Glu Gln Pro Gly Asn Thr Ile Ser Ala Gly  
 1 5 10 15  
 Gln Glu Asp Phe Pro Ser Val Leu Leu Glu Thr Ala Ala Ser Xaa Pro  
 20 25 30  
 Ser Leu Ser Pro Leu Ser Ala Ala Ser Phe Lys Glu His Glu Tyr Leu  
 35 40 45  
 Gly Asn Leu Ser Thr Val Leu Pro Thr Glu Gly Thr Leu Gln Glu Asn  
 50 55 60  
 Val Ser Glu Ala Ser Lys Glu Val Ser Glu Lys Ala Lys Thr Leu Leu  
 65 70 75 80  
 Ile Asp Arg Asp Leu Thr Glu Phe Ser Glu Leu Glu Tyr Ser Glu Met  
 85 90 95  
 Gly Ser Ser Phe Ser Val Ser Pro Lys Ala Glu Ser Ala Val Ile Val  
 100 105 110  
 Ala Asn Pro Arg Glu Glu Ile Ile Val Lys Asn Lys Asp Glu Glu Glu  
 115 120 125  
 Lys Leu Val Ser Asn Asn Ile Leu His Xaa Gln Gln Glu Leu Pro Thr  
 130 135 140  
 Ala Leu Thr Lys Leu Val Lys Glu Asp Glu Val Val Ser Ser Glu Lys  
 145 150 155 160  
 Ala Lys Asp Ser Phe Asn Glu Lys Arg Val Ala Val Glu Ala Pro Met  
 165 170 175  
 Arg Glu Glu Tyr Ala Asp Phe Lys Pro Phe Glu Arg Val Trp Glu Val  
 180 185 190  
 Lys Asp Ser Lys Glu Asp Ser Asp Met Leu Ala Ala Gly Gly Lys Ile  
 195 200 205  
 Glu Ser Asn Leu Glu Ser Lys Val Asp Lys Lys Cys Phe Ala Asp Ser  
 210 215 220  
 Leu Glu Gln Thr Asn His Glu Lys Asp Ser Glu Ser Ser Asn Asp Asp  
 225 230 235 240  
 Thr Ser Phe Pro Ser Thr Pro Glu Gly Ile Lys Asp Arg Ser Gly Ala  
 245 250 255  
 Tyr Ile Thr Cys Ala Pro Phe Asn Pro Ala Ala Thr Glu Ser Ile Ala  
 260 265 270  
 Thr Asn Ile Phe Pro Leu Leu Gly Asp Pro Thr Ser Glu Asn Lys Thr  
 275 280 285  
 Asp

<210> 5  
 <211> 1122  
 <212> DNA  
 <213> HOMO SAPIENS

<400> 5  
 atggaagacc tggaccagtc tcctctggtc tcgtcctcgg acagcccacc ccggccgcag 60  
 cccgcgttca agtaccagtt cgtgagggag ccgaggagac aggaggaaga agaggaggag 120  
 gaagaggagg acgaggacga agacctggag gagctggagg tgctggagag gaagcccgcc 180  
 gccgggctgt ccggggcccc agtgcccacc gccctgccc ccggcgccgc cctgatggac 240  
 ttgggaaatg acttcgtgcc gccggcgccc cggggacccc tgccggccgc tccccccgtc 300  
 gccccggagc ggcagccgtc ttgggaccgg agcccgtgt cgtcgaccgt gcccgcccca 360  
 tccccgctgt ctgctgcgc agtatcgccc tccaagctcc ctgaggacga cgagcctccg 420  
 gcccggcctc cccctcctcc cccggccagc gtgagccccc aggcagagcc cgtgtggacc 480  
 ccgcccagccc cggctccgc cggccccccc tccaccccgg ccgcccacca gcgcaggggc 540  
 tcctcgggct cagtgttgt tgacctctg tactggagag acattaagaa gactggagtg 600  
 gtgtttggtg ccagcctatt cctgctgctt tcattgacag tattcagcat tgtgagcgta 660  
 acagcctaca ttgccttggc cctgctctct gtgacctca gctttaggat atacaagggt 720

03/17/05 15:09 FAX 202 828 1700

```

gtgatccaag ctatccagaa atcagatgaa ggccacccat tcagggcata tctggaatct 780
gaagttgcta tatctgagga gttgggtcag aagtacagta attctgctct tggtcattgtg 840
aactgcacga taaaggaact caggcgccctc ttcttagttg atgatttagt tgattctctg 900
aagtttgacg tgttgatgtg ggtatttacc tatgttggtg ccttggttaa tggctctgaca 960
ctactgattt tggctctcat ttactcttc agtgttcctg ttatttatga acggcatcag 1020
gcacagatag atcattatct aggacttgca aataagaatg ttaaagatgc tatggctaaa 1080
atccaagcaa aaatccctgg attgaagcgc aaagctgaat ga 1122

```

```

<210> 6
<211> 373
<212> PRT
<213> HOMO SAPIENS

```

```

<400> 6
Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro
1 5 10 15
Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu
20 25 30
Asp Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp
35 40 45
Leu Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly Leu Ser
50 55 60
Ala Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala Pro Leu Met Asp
65 70 75 80
Phe Gly Asn Asp Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala
85 90 95
Ala Pro Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro
100 105 110
Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Val
115 120 125
Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro
130 135 140
Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp Thr
145 150 155 160
Pro Pro Ala Pro Ala Pro Ala Ala Pro Pro Ser Thr Pro Ala Ala Pro
165 170 175
Lys Arg Arg Gly Ser Ser Gly Ser Val Val Val Asp Leu Leu Tyr Trp
180 185 190
Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala Ser Leu Phe Leu
195 200 205
Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr Ala Tyr Ile
210 215 220
Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile Tyr Lys Gly
225 230 235 240
Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe Arg Ala
245 250 255
Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu Val Gln Lys Tyr
260 265 270
Ser Asn Ser Ala Leu Gly His Val Asn Cys Thr Ile Lys Glu Leu Arg
275 280 285
Arg Leu Phe Leu Val Asp Asp Leu Val Asp Ser Leu Lys Phe Ala Val
290 295 300
Leu Met Trp Val Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr
305 310 315 320
Leu Leu Ile Leu Ala Leu Ile Ser Leu Phe Ser Val Pro Val Ile Tyr
325 330 335

```

09359263.072299


Glu Arg His Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala Asn Lys  
340 345 350  
Asn Val Lys Asp Ala Met Ala Lys Ile Gln Ala Lys Ile Pro Gly Leu  
355 360 365  
Lys Arg Lys Ala Glu  
370

662220 80265E60

PRINT OF DRAWING  
AS ORIGINALLY FILED

1/1

Figure 1




00359208 072809

PRINT OF DRAWING  
AS ORIGINALLY FILED

1/1

Figure 1



062270.072239

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**